Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
164 hedge funds and large institutions have $181M invested in Antares Pharma, Inc. in 2020 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 39 increasing their positions, 56 reducing their positions, and 16 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
31% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 16
3% more funds holding
Funds holding: 159 → 164 (+5)
7% less capital invested
Capital invested by funds: $195M → $181M (-$14.3M)
30% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 56
60% less call options, than puts
Call options by funds: $345K | Put options by funds: $865K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$3.34M |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$1.53M |
| 3 |
SAM
Silvercrest Asset Management
New York
|
+$1.25M |
| 4 |
AC
Armistice Capital
New York
|
+$1.18M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWM
Centric Wealth Management
Chicago,
Illinois
|
-$9.89M |
| 2 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
-$1.76M |
| 3 |
QI
QS Investors
New York
|
-$1.42M |
| 4 |
Millennium Management
New York
|
-$1.28M |
| 5 |
State Street
Boston,
Massachusetts
|
-$1.12M |
ATRS Hedge Fund Activity: Q3 2020 in Review
164 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q3 2020, worth a combined $181M — down 7.3% from $195M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ATRS positions and 16 closed out — a net gain of 5 holders — while 39 added to existing stakes and 56 trimmed.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $3.34M. The largest seller was Centric Wealth Management, exiting entirely with an estimated $9.89M sold.
- 164 institutional investors held Antares Pharma, Inc. (ATRS) as of Q3 2020, up from 159 in Q2 2020.
- Funds reported $181M of Antares Pharma, Inc. stock for Q3 2020, down 7.3% quarter-over-quarter.
- 21 funds opened new Antares Pharma, Inc. positions in Q3 2020 and 16 closed out, a net change of +5 holders.
- The largest Antares Pharma, Inc. buyer in Q3 2020 was Stonepine Capital Management, an estimated $3.34M added.
- The largest Antares Pharma, Inc. seller in Q3 2020 was Centric Wealth Management, an estimated $9.89M sold.
Based on aggregated 13F filings for Q3 2020.